BACKGROUND AND OBJECTIVE: The prevalence of childhood obesity has risen considerably on a global scale during the past decades, and the condition is associated with increased risk of morbidity. The objective is to describe the Uppsala Longitudinal Study of Childhood Obesity (ULSCO) cohort, including some baseline data, and outline addressed research areas that aim at identifying factors implicated in and contributing to development of obesity and obesity-related diseases, including type 2 diabetes. METHODS: Severely obese and lean control subjects are examined at enrollment and at subsequent annual visits by using detailed questionnaires, anthropometric measurements, indirect calorimetry, and functional tests such as oral glucose tolerance tests. Some subjects undergo additional characterization with MRI, subcutaneous fat biopsies, frequent blood sampling, and hyperglycemic clamps. Biological samples are obtained and stored in a biobank. RESULTS: Active recruitment started in 2010, and standard operating procedures have been established. A high participation rate and annual follow-ups have resulted in a cohort exceeding 200 subjects, including 45 lean controls (as of October 2013). Initial research focus has been on traits of the metabolic syndrome, hyperinsulinemia and identifying risk factors for type 2 diabetes. CONCLUSIONS: The ULSCO cohort serves as an important resource in defining and understanding factors contributing to childhood obesity and development of obesity-related diseases. Given the comprehensive characterization of the cohort, factors contributing to disease development and progression can be identified. Such factors are further evaluated for their mechanistic role and significance, and noncommunicable metabolic diseases are especially addressed and considered.
BACKGROUND AND OBJECTIVE: The prevalence of childhood obesity has risen considerably on a global scale during the past decades, and the condition is associated with increased risk of morbidity. The objective is to describe the Uppsala Longitudinal Study of Childhood Obesity (ULSCO) cohort, including some baseline data, and outline addressed research areas that aim at identifying factors implicated in and contributing to development of obesity and obesity-related diseases, including type 2 diabetes. METHODS: Severely obese and lean control subjects are examined at enrollment and at subsequent annual visits by using detailed questionnaires, anthropometric measurements, indirect calorimetry, and functional tests such as oral glucose tolerance tests. Some subjects undergo additional characterization with MRI, subcutaneous fat biopsies, frequent blood sampling, and hyperglycemic clamps. Biological samples are obtained and stored in a biobank. RESULTS: Active recruitment started in 2010, and standard operating procedures have been established. A high participation rate and annual follow-ups have resulted in a cohort exceeding 200 subjects, including 45 lean controls (as of October 2013). Initial research focus has been on traits of the metabolic syndrome, hyperinsulinemia and identifying risk factors for type 2 diabetes. CONCLUSIONS: The ULSCO cohort serves as an important resource in defining and understanding factors contributing to childhood obesity and development of obesity-related diseases. Given the comprehensive characterization of the cohort, factors contributing to disease development and progression can be identified. Such factors are further evaluated for their mechanistic role and significance, and noncommunicable metabolic diseases are especially addressed and considered.
Authors: Valérie Julian; Peter Bergsten; Gael Ennequin; Anders Forslund; Hakan Ahlstrom; Iris Ciba; Marie Dahlbom; Dieter Furthner; Julian Gomahr; Joel Kullberg; Katharina Maruszczak; Katharina Morwald; Roger Olsson; Thomas Pixner; Anna Schneider; Bruno Pereira; Suzanne Ring-Dimitriou; David Thivel; Daniel Weghuber Journal: Eur J Pediatr Date: 2022-06-30 Impact factor: 3.860
Authors: Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman Journal: Surg Obes Relat Dis Date: 2018-03-23 Impact factor: 4.734
Authors: Johan Staaf; Sarojini J K A Ubhayasekera; Ernest Sargsyan; Azazul Chowdhury; Hjalti Kristinsson; Hannes Manell; Jonas Bergquist; Anders Forslund; Peter Bergsten Journal: Pediatr Res Date: 2016-04-11 Impact factor: 3.756
Authors: Katharina Mörwald; Elmar Aigner; Peter Bergsten; Susanne M Brunner; Anders Forslund; Joel Kullberg; Hakan Ahlström; Hannes Manell; Kirsten Roomp; Sebastian Schütz; Fanni Zsoldos; Wilfried Renner; Dieter Furthner; Katharina Maruszczak; Stephan Zandanell; Daniel Weghuber; Harald Mangge Journal: Front Endocrinol (Lausanne) Date: 2020-06-18 Impact factor: 5.555
Authors: Elin Lundström; Joy Ljungberg; Jonathan Andersson; Hannes Manell; Robin Strand; Anders Forslund; Peter Bergsten; Daniel Weghuber; Katharina Mörwald; Fanni Zsoldos; Kurt Widhalm; Matthias Meissnitzer; Håkan Ahlström; Joel Kullberg Journal: Pediatr Obes Date: 2019-07-09 Impact factor: 4.000
Authors: Valérie Julian; Iris Ciba; Roger Olsson; Marie Dahlbom; Dieter Furthner; Julian Gomahr; Katharina Maruszczak; Katharina Morwald; Thomas Pixner; Anna Schneider; Bruno Pereira; Martine Duclos; Daniel Weghuber; David Thivel; Peter Bergsten; Anders Forslund Journal: Nutrients Date: 2021-12-24 Impact factor: 5.717
Authors: Johan Staaf; Viktor Labmayr; Katharina Paulmichl; Hannes Manell; Jing Cen; Iris Ciba; Marie Dahlbom; Kirsten Roomp; Christian-Heinz Anderwald; Matthias Meissnitzer; Reinhard Schneider; Anders Forslund; Kurt Widhalm; Jonas Bergquist; Håkan Ahlström; Peter Bergsten; Daniel Weghuber; Joel Kullberg Journal: Pancreas Date: 2017-03 Impact factor: 3.327
Authors: Iris Ciba; Loretta S Warnakulasuriya; Adikaram V N Adikaram; Peter Bergsten; Marie Dahlbom; Manel M A Fernando; Elisabet Rytter; Dulani L Samaranayake; K D Renuka Ruchira Silva; V Pujitha Wickramasinghe; Anders H Forslund Journal: Pediatr Diabetes Date: 2020-11-04 Impact factor: 3.409